Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders
25. September 2024 08:30 ET
|
Entera Bio Ltd.; OPKO Health, Inc.
JERUSALEM and MIAMI, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (Entera), a leader in the development of orally delivered peptides, and OPKO Health, Inc. (NASDAQ: OPK) (OPKO)...
Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome
20. März 2024 08:00 ET
|
Entera Bio Ltd.
JERUSALEM, March 20, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, announced today positive...
Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development
14. November 2023 07:30 ET
|
Entera Bio Ltd.
JERUSALEM, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”), a leader in the development of orally delivered peptides and small therapeutic proteins,...
Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes
12. September 2023 08:30 ET
|
Entera Bio Ltd.
JERUSALEM, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX, “Entera”) and OPKO Biologics, Inc., a subsidiary of OPKO Health, Inc. (NASDAQ: OPK, “OPKO”) have entered into a Research...
Sian Capital Urges OPKO Health to Address Apparently Misleading 4Q’20 Guidance
13. Januar 2021 06:00 ET
|
Sian Capital, LLC
NEW YORK, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Sian Capital, LLC (together with its affiliates, “Sian” or “we”), a sizable stockholder of OPKO Health, Inc. (NASDAQ: OPK) (“OPKO” or the “Company”),...
Sian Capital Sends Letter to OPKO Health Regarding its Decision to Apparently Withhold Rayaldee From Many Patients Amidst COVID-19’s Second Wave
20. November 2020 16:45 ET
|
Sian Capital, LLC
Believes OPKO Should Promptly Distribute FDA-Reviewed Rayaldee to Help Treat COVID-19 in the U.S. and Europe Highlights the Opportunity Being Squandered by Dr. Frost and the Board as Europe...
Sian Capital Issues Open Letter to Stockholders of OPKO Health
12. November 2020 18:30 ET
|
Sian Capital, LLC
Highlights that Just Two Weeks after Sian Capital Sent Its 220 Demand Letter to OPKO, the Company has Agreed to Release A Subset of the Documents Requested, Which We Believe Will Validate our...
Sian Capital Highlights Paths to Meaningful Value Creation at OPKO Health
29. Oktober 2020 17:20 ET
|
Sian Capital, LLC
Issues Presentation Outlining Viable Paths to Unlocking OPKO’s Intrinsic Value, Which is ~3x the Company’s Current Market Capitalization Based on its Diagnostic and Pharmaceutical Assets Releases...
TUESDAY DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against OPKO Health, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
09. November 2018 15:41 ET
|
Schall Law
LOS ANGELES, Nov. 09, 2018 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against OPKO Health, Inc. (“OPKO” or...
IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against OPKO Health, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
29. Oktober 2018 15:06 ET
|
Schall Law
LOS ANGELES, Oct. 29, 2018 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against OPKO Health, Inc. (“OPKO” or...